Join Growin Stock Community!

Ocugen, inc.OCGN.US Overview

US StockHealthcare
(No presentation for OCGN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

OCGN AI Insights

OCGN Overall Performance

OCGN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

OCGN Recent Performance

3.02%

Ocugen, inc.

0.05%

Avg of Sector

-0.31%

S&P500

OCGN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

OCGN Key Information

OCGN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

OCGN Profile

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Price of OCGN

OCGN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

OCGN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.20
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
110.94
PB Ratio
172.79
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-1192.22%
Revenue Growth (YoY)
-42.43%
Profit Growth (YoY)
-42.43%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.20
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
110.94
PB Ratio
172.79
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-1192.22%
Revenue Growth (YoY)
-42.43%
Profit Growth (YoY)
-42.43%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
  • When is OCGN's latest earnings report released?

    The most recent financial report for Ocugen, inc. (OCGN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating OCGN's short-term business performance and financial health. For the latest updates on OCGN's earnings releases, visit this page regularly.

  • What is the operating profit of OCGN?

    According to the latest financial report, Ocugen, inc. (OCGN) reported an Operating Profit of -17.63M with an Operating Margin of -1,005.99% this period, representing a decline of 33% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is OCGN's revenue growth?

    In the latest financial report, Ocugen, inc. (OCGN) announced revenue of 1.75M, with a Year-Over-Year growth rate of 54.23%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does OCGN have?

    As of the end of the reporting period, Ocugen, inc. (OCGN) had total debt of 32.96M, with a debt ratio of 0.57. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does OCGN have?

    At the end of the period, Ocugen, inc. (OCGN) held Total Cash and Cash Equivalents of 32.88M, accounting for 0.57 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does OCGN go with three margins increasing?

    In the latest report, Ocugen, inc. (OCGN) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -1,005.99%%, and net margin of -1,144.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess OCGN's profit trajectory and future growth potential.

  • Is OCGN's EPS continuing to grow?

    According to the past four quarterly reports, Ocugen, inc. (OCGN)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of OCGN?

    Ocugen, inc. (OCGN)'s Free Cash Flow (FCF) for the period is -13.01M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 10.43% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.